Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients
Por:
Feliu J, Heredia-Soto V, Gironés R, Jiménez-Munarriz B, Saldaña J, Guillén-Ponce C and Molina-Garrido MJ
Publicada:
1 abr 2020
Ahead of Print:
25 jun 2019
Resumen:
The elderly form a very heterogeneous group in relation to their general health state, degree of dependence, comorbidities, performance status, physical reserve and geriatric situation, so cancer treatment in the older patient remains a therapeutic challenge. The physiological changes associated with aging increase the risk of developing a serious toxicity induced by chemotherapy treatment, as well as other undesirable consequences as hospitalizations, dependence and non-compliance with treatment, that can negatively affect survival, quality of life and treatment efficacy. The use of hematopoietic growth factors and other active supportive interventions in the elderly can help prevent and/or alleviate these toxicities. However, we have little data on the efficacy and tolerance of support treatments in the older patient. The objective of this work is to review the most frequent toxicities of oncological treatments in the elderly and their management.
Filiaciones:
Feliu J:
Medical Oncology Department, H. Universitario La Paz, CIBERONC, Paseo de la Castellana 261, 28046, Madrid, Spain.
Heredia-Soto V:
Medical Oncology Department, H. Universitario La Paz, CIBERONC, Paseo de la Castellana 261, 28046, Madrid, Spain
:
Medical Oncology Department, H. Lluís Alcanyís. Xàtiva, Valencia, Spain
Jiménez-Munarriz B:
Medical Oncology Department, H. Universitario Clara Campal, Madrid, Spain
Saldaña J:
Medical Oncology Department, Instituto Catalán de Oncología, Hospitalet, Barcelona, Spain
Guillén-Ponce C:
Medical Oncology Department, H. Universitario Ramón Y Cajal, Madrid, Spain
Molina-Garrido MJ:
Medical Oncology Department, H. Virgen de La Luz, Cuenca, Spain
|